Cited by 164Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersSingle-cell and spatial transcriptomics

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome

Open access

Liudahl, Shannon M., Betts, Courtney B., Sivagnanam, Shamilene, Morales-Oyarvide, Vicente, da Silva, Annacarolina, Yuan, Chen, Hwang, Samuel, Grossblatt-Wait, Alison, Leis, Kenna R., Larson, William, Lavoie, Meghan B., Robinson, Padraic, Dias Costa, Andressa, Väyrynen, Sara A., Clancy, Thomas E., Rubinson, Douglas A., Link, Jason, Keith, Dove, Horton, Wesley, Tempero, Margaret A., Vonderheide, Robert H., Jaffee, Elizabeth M., Sheppard, Brett, Goecks, Jeremy, Sears, Rosalie C., Park, Byung S., Mori, Motomi, Nowak, Jonathan A., Wolpin, Brian M., Coussens, Lisa M.·2021·Cancer Discovery

DOI 10.1158/2159-8290.cd-20-0841PMC PMC8338775

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Immunotherapies targeting aspects of T cell functionality are efficacious in many solid tumors, but pancreatic ductal adenocarcinoma (PDAC) remains refractory to these treatments. Deeper understanding of the PDAC immune ecosystem is needed to identify additional therapeutic targets and predictive biomarkers for therapeutic response and resistance monitoring. To address these needs, we quantitatively evaluated leukocyte contexture in 135 human PDACs at single-cell resolution by profiling density and spatial distribution of myeloid and lymphoid cells within histopathologically defined regions of surgical resections from treatment-naive and presurgically (neoadjuvant)–treated patients and biopsy specimens from metastatic PDAC. Resultant data establish an immune atlas of PDAC heterogeneity, identify leukocyte features correlating with clinical outcomes, and, through an in silico study, provide guidance for use of PDAC tissue microarrays to optimally measure intratumoral immune heterogeneity. Atlas data have direct applicability as a reference for evaluating immune responses to investigational neoadjuvant PDAC therapeutics where pretherapy baseline specimens are not available. Significance: We provide a phenotypic and spatial immune atlas of human PDAC identifying leukocyte composition at steady state and following standard neoadjuvant therapies. These data have broad utility as a resource that can inform on leukocyte responses to emerging therapies where baseline tissues were not acquired. This article is highlighted in the In This Issue feature, p. 1861

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-20-0841

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer Statistics, 2021
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Self-citation
CellProfiler: image analysis software for identifying and quantifying cell phenotypes
Carpenter, A. E., Jones, T. R., Lamprecht, M. R., Clarke, C., Kang, I. H., Friman, O., Guertin, D. A., Chang, J. H., Lindquist, R. A., Moffat, J., et al. (2006) · Genome biology · doi:10.1186/gb-2006-7-10-r100 · Cited by 5,212
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,591

Flagged first, then by citations

Show all 52 references

Research works printed but not linked: 1

Johnson, 2020, An integrated clinical, omic, and image atlas of an evolving metastatic breast cancer, bioRxiv, 2020, 12.03.408500

Sorted by citations

Items 101–164 of 164

Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma
Merali, N., Jessel, M.-D., Arbe-Barnes, E. H., Lee, W., Gismondi, M., Chouari, T. A. M., O’Brien, J., Patel, B. Y., Osei‐Bordom, D., Rockall, T., et al. (2024) · HPB · doi:10.1016/j.hpb.2024.04.009 · Cited by 7
Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
Ehlers, F. A. I., Blise, K. E., Betts, C. B., Sivagnanam, S., Kooreman, L. F. S., Hwang, E. S., Bos, G. M. J., Wieten, L., & Coussens, L. M. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-01964-4 · Cited by 7
Self-citation
IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer
Markov, S. D., Caffrey, T. C., O’Connell, K. A., Grunkemeyer, J. A., Shin, S. C., Hanson, R. L., Patil, P. P., Shukla, S. K., Gonzalez, D. V., Crawford, A. J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0368 · Cited by 7
Self-citation
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model
Veinalde, R., Pidelaserra-Martí, G., Moulin, C., Tan, C. L., Schäfer, T. E., Kang, N. H., Ball, C. R., Leichsenring, J., Stenzinger, A., Kaderali, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096162 · Cited by 9
Innate Immunity and Platelets: Unveiling Their Role in Chronic Pancreatitis and Pancreatic Cancer
Blümke, J., Schameitat, M., Verma, A., Limbecker, C., Arlt, E., Kessler, S. M., Kielstein, H., Krug, S., Bazwinsky‐Wutschke, I., & Hämmerle, M. (2025) · Cancers · doi:10.3390/cancers17101689 · Cited by 7
High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Greene, E. R., Horvat, N. K., Doxie, D. B., Parihar, V. C., Kim, J., Herting, C. J., Grundy, E. E., Ruffin, A. T., Krasinskas, A. M., Maithel, S. K., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1697 · Cited by 6
Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions
Nagaraju, G. P., Nellipudi, H. R., Ganji, C., Kuppala, V., Ganji, S. P., Kumari, S., Farran, B., Srilatha, M., Guenter, R. E., & El‐Rayes, B. F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02705-5 · Cited by 7
The preclinical gap in pancreatic cancer and radiotherapy
Tesson, M., & Morton, J. P. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050703 · Cited by 6
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer
Lopez, C. D., Kardosh, A., Chen, E. Y.-S., Pegna, G. J., Guimarães, A. R., Foster, B. R., Brinkerhoff, B. T., Goodyear, S. M., Lim, J.-Y., Taber, E. N., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2395235 · Cited by 6
Self-citation
Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway
la Torre, J. D., Joshi, U., Sonowal, H., Kuang, Y., Ren, T., Chen, D.-H., Tharuka, M. D. N., Nguyen-Ta, K., Gros, H. L., Mikulski, Z., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0129 · Cited by 5
Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial
Wainberg, Z. A., Link, J. M., Premji, A., Zheng, S., Srienc, M. K., Hammons, M., Kim, S., Li, L., Liu, Z., Tsvetkova, O., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68976-2 · Cited by 7
Self-citation
Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes
Jassowicz, L., Feng, F., Warta, R., Heinicke, F., Wöllner, A., Briesch, H., Sor, F., Soller, J., Lotsch, C., Wong, J. K. L., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.016 · Cited by 6
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial
Perez, K. J., Costa, A. D., Jordan, A., Karasic, T. B., Elganainy, D., Kim, S., Yuan, C., Gui, D. Y., Tan, R., Hong, S. C., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01165-8 · Cited by 8
Self-citation
Topographic analysis of pancreatic cancer by TMA and digital spatial profiling reveals biological complexity with potential therapeutic implications
Bingham, V., Harewood, L., McQuaid, S., Craig, S. G., Revolta, J. F., Kim, C. S., Srivastava, S., Quezada-Marín, J. I., Humphries, M. P., & Salto‐Tellez, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-62031-0 · Cited by 5
Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer
Beatty, G. L., & Jaffee, E. M. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae065 · Cited by 5
Self-citation
Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse modelPreprint
English, I. A., Worth, P. J., Hawthorne, K., Vergara, M., Pelz, K. R., Kiemen, A. L., Shah, V., Blise, K. E., Pelz, C., Tsuda, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.14.664767 · Cited by 6
Self-citation
Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer
Um, Y. J., Kwak, D., Kim, S. Y., Chang, H. J., Yum, S. H., Hwang, J.-S., Kim, J. E., Jung, J. Y., Hong, S. H., Park, S., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115653 · Cited by 4
TRPA1 Contributes to FGFR2c Signaling and to Its Oncogenic Outcomes in Pancreatic Ductal Adenocarcinoma-Derived Cell Lines
Mancini, V., Raffa, S., Fiorio, A., French, D., Torrisi, M. R., Ranieri, D., & Belleudi, F. (2024) · Cancers · doi:10.3390/cancers16030609 · Cited by 4
Enhanced safety and efficacy profile of CD40 antibody upon encapsulation in pHe-triggered membrane-adhesive nanoliposomes
Althobaiti, S., Parajuli, P., Luong, D., Sau, S., Polin, L., Kim, S., Ge, Y., Iyer, A. K., & Gavande, N. S. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2446008 · Cited by 4
B cells present a double-sided effect in digestive system tumors: a review for tumor microenvironment
Xu, J., Lu, W., Yang, J., & Liu, X. (2024) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-23-127 · Cited by 4
Context-specific GITR agonism potentiates anti-PD-L1 and CD40-based immuno-chemotherapy combination in heterogeneous pancreatic tumorsPreprint
Ragulan, C., Desai, K., Lawrence, P. V., Ikami, Y., Aalam, S. M. M., Hari, P. S., Kannan, N., Cunningham, D., Starling, N., & Sadanandam, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.16.545301 · Cited by 4
Single-cell immune multi-omics and repertoire analyses in pancreatic ductal adenocarcinoma reveal differential immunosuppressive mechanisms within different tumour microenvironmentsPreprint
Sivakumar, S., Jainarayanan, A., Arbe-Barnes, E. H., Sharma, P. K., Leathlobhair, M. N., Amin, S., Heij, L. R., Hegde, S., Magen, A., Tucci, F. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.31.555730 · Cited by 4
Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer
Zhang, S., Cui, M., Huang, X., Feng, X., Xiao, R., Liu, Q., Bai, J., Han, X., Liu, X., Xu, W., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102660 · Cited by 3
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment
Maltez, V. I., Arora, C., Gribbin, K. P., Caruso, B. P., Haerr, M. E., Sor, R., Lian, Q., Blise, K. E., Sivagnanam, S., Sears, R. C., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.011 · Cited by 3
Self-citation
Promising Therapeutic Approach in Pancreatic Cancer: Metabolism-Related Genes
Choe, S., Kwak, W., Kim, E., Shin, S., Shin, M., Koh, H. J., & Yoon, H. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904137 · Cited by 3
Quantitative analysis of T cell subsets in a population of Black women with invasive breast cancer
Omilian, A. R., Mendicino, L., George, A., Darabnoushtehrani, T., Ondracek, R. P., Bshara, W., Hong, C., Qin, B., Bandera, E. V., Khoury, T., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00780-5 · Cited by 2
Heterogeneity of glycan biomarker clusters as an indicator of recurrence in pancreatic cancer
Wisniewski, L., Braak, S., Klamer, Z. L., Gao, C., Shi, C., Allen, P. J., & Haab, B. B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135405 · Cited by 2
Rapid multiplex immunohistochemistry for characterizing tumor-immune microenvironment
Kimura, A., Tsujikawa, T., Morimoto, H., Saburi, S., Mitsuda, J., Mukudai, S., Nagao, H., Shibata, S., Ogi, H., Miyagawa‐Hayashino, A., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33830 · Cited by 2
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir, T., Moloney, C., & Mahalingam, D. (2025) · Cancers · doi:10.3390/cancers17050715 · Cited by 2
Road Map to Defeat Pancreatic Cancer
Ferguson, L. P., & Tuveson, D. A. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060624-044323 · Cited by 2
Tumor-dependent myeloid and lymphoid cell recruitment in genO-BRGSF-HIS mice: a novel tool for evaluating immunotherapies
Martin, G. H., Hedir, S., Creusat, F., Gonon, A., Marguier, A., Martin-Jeantet, P., Nouveau, L., Cons, L., Depontieu, F., Moine, V., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1624724 · Cited by 2
A Growing Hope for Earlier Detection of Pancreatic Cancer
Rosenthal, M. H., Schawkat, K., & Wolpin, B. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.07.080 · Cited by 2
Self-citation
Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinomaPreprint
Guo, Y., Finan, J. M., Bartlett, A. Q., Sivagnanam, S., Blise, K. E., Kirchberger, N. C., Betre, K., McCarthy, G. A., Hawthorne, K., Chen, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.07.632847 · Cited by 2
Self-citation
Tumor-immune trajectory context connects static tissue architecture to clinical outcomesPreprint
Cramer, E. M., Heiland, R. W., da Rocha, H. L., Bergman, D. R., Gray, J. W., Mills, G. B., Fertig, E. J., Macklin, P., Heiser, L. M., & Chang, Y. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.26.714521 · Cited by 2
Deciphering the heterogeneity of epithelial cells in pancreatic ductal adenocarcinoma: implications for metastasis and immune evasion
Liu, J., Li, H., Lin, X., Xiong, J., Wu, G., Ding, L., & Lin, B. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03793-3 · Cited by 1
Neoadjuvant therapy-induced immune dynamics and myeloid-associated resistance in advanced head and neck cancer
Kimura, A., Mitsuda, J., Yoshimura, K., Saburi, S., Murakami, N., Sakurai, N., Yoshizawa, K., Morimoto, H., Mukudai, S., Nagao, H., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00954-1 · Cited by 1
Comparative Analysis of Pathology Foundation Models for Automated Detection of Tertiary Lymphoid Structures in Hematoxylin-and-Eosin-Stained Digital Pathology Images
Guan, M., Sun, Y., Belete, M. K., Muthuswamy, A., Farma, M., Kaufmann, J., Lechpammer, M., Sridhar, S., Higgs, B. W., & Si, H. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0086 · Cited by 1
Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types
Yu, Y., Li, Y., Wang, J., Zhu, Y.-J., Zhang, Z., Xiao, Z., Chen, Y., Qu, Y., Han, L., & Zhang, H. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00757-5 · Cited by 2
Remodeling the pancreatic tumor microenvironment by chemotherapy: New opportunities for combination therapy
Tang, Y., Luo, X., Zhou, F., Gu, J., Li, X. F., Yang, G., Zhang, T. P., & You, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189604 · Cited by 1
CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer
Li, Q., Hoffman, M. T., Chun, J.-H., Parent, B. D., Hambitzer, F., Peprah, F., Kureshi, C. T. S., Lim, B. S., Chang, E., Walsh, M. J., et al. (2026) · Cell · doi:10.1016/j.cell.2026.08.045 · Cited by 1
Self-citation
Simulating the Tumor Microenvironment for Immune Cell Interactions via Deployable Extrusion BioprintingPreprint
Mazzaglia, C., Sheng, Y., Rodrigues, L. N., Lei, I. M., Shields, J. D., & Huang, Y. Y. S. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.08.487692 · Cited by 1
Invasion status stratifies the composition of the human pancreatic cancer perineural nichePreprint
Hussain, Z., Yarlagadda, D. V. K., Li, Q., Tezcan, N., Stupakov, P., Sadatrezaei, G., Wong, R. J., Massagué, J., Tarcan, Z. C., Baştürk, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.05.743048 · Cited by 1
Supplementary Fig S2 from IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer
Markov, S. D., Caffrey, T. C., O’Connell, K. A., Grunkemeyer, J. A., Shin, S. C., Hanson, R., Patil, P. P., Shukla, S. K., Gonzalez, D. V., Crawford, A. J., et al. (2023) · doi:10.1158/1535-7163.22522485
Self-citation
Data from IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer
Markov, S. D., Caffrey, T. C., O’Connell, K. A., Grunkemeyer, J. A., Shin, S. C., Hanson, R., Patil, P. P., Shukla, S. K., Gonzalez, D. V., Crawford, A. J., et al. (2023) · doi:10.1158/1535-7163.c.6543399.v1
Self-citation
Data from PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups
Karamitopoulou, E., Andreou, A. G., de Mortanges, A. P., Tinguely, M., Gloor, B., & Perren, A. A. (2023) · doi:10.1158/2326-6066.c.6550536.v1
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal AdenocarcinomaPreprint
Greene, E. R., Horvat, N. K., Doxie, D. B., Parihar, V. C., Kim, J., Herting, C. J., Grundy, E. E., Ruffin, A. T., Krasinskas, A. M., Maithel, S. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.18.649381
Single cell transcriptomics in prostate cancer research
Ринатовна, А. Э., Вакилевна, Ш. Ю., Gainullina, D. K., Shmelkova, P., Kalimullina, L., Павлов, В. Н., & Enikeeva, K. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-sct-3214
Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacyPreprint
Chen, C., Gribbin, K. P., Li, X., Ozmen, T. Y., Ozmen, F., Sivagnanam, S., Kim, J., Blise, K. E., Yang, X., Zhang, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.21.683745
Self-citation
A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwayPreprint
Tsuda, M., Keith, D. J., Daniel, C. J., Pelz, C., Blise, K. E., Ozmen, T. Y., Ozmen, F., Hawthone, K., Eng, J. R., Li, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693851
Self-citation
Investigation of a 47Sc-radiolabelled PDGFRβ-targeted affibody in SPECT imaging and radiotherapy for pancreatic cancer
Liu, R., Su, D., Liao, Y., Zhao, L., Li, B., Chen, Y., Cao, Q., Zhang, J., & Cai, H. (2026) · BMC Cancer · doi:10.1186/s12885-025-15506-w
ImmunoPheno: A Computational Framework for Data-Driven Design and Analysis of Immunophenotyping ExperimentsPreprint
Wu, L., Nguyen, M. A., Yang, Z., Potluri, S., Sivagnanam, S., Kirchberger, N. C., Joshi, A. S., Ahn, K. J., Tumulty, J. S., Cabrera, E. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.01.703134
Self-citation
Identification et ciblage de dialogues tumeur-stroma impliqués dans l'agressivité de l'adénocarcinome canalaire pancréatique
Brunel, A. (2022) · theses.fr (ABES) · doi:10.70675/4f9e08fez29b2z4a0dzabf6z424c6decb590
Necrosis, microbial cues and macrophage-driven immune escape in pancreatic cancer
Cordani, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218553
Spatially resolved transcriptomic and proteomic profiling reveals cell interaction programs that predict Barrett’s esophagus progressionPreprint
Monarrez, I., Kim, E. N., Moon, K., Baker, A. M., Chen, P. Z., Bressan, D., Miremadi, A., di Pietro, M., Hannon, G. J., Graham, T. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.08.723546
Integration of pathomics and single-cell omics in pancreatic ductal adenocarcinoma: Applications and clinical translation prospects
Yan, X., Xu, H.-Y., Liu, J.-W., Yang, Z.-Y., & Zhu, Q. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i5.119864
Conserved Metastatic Cell States and Spatial Immune Microenvironment Remodeling Define Pancreatic Cancer Liver MetastasesPreprint
Mandloi, A., Larson, C. R., Tran, T. M., Roy, S., Khaliq, A. M., Fang, Y.-H. D., Baines, J., Laube, R., Patel, M., Risley, C. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.27.728281
Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancerPreprint
Kang, S., Parikh, M., Pappas, L., Bi, L., Koenig, J. L., Yeap, B. Y., Carzo, N., Grillo, T. M., Baiev, I., Asupoto, O., et al. (2026) · medRxiv · doi:10.64898/2026.08.06.26359422
Self-citation
A cyclooxygenase-2 associated pro-tumorigenic inflammatory signature predicts outcome after surgery in lung cancerPreprint
Fife, V. E. R., Bromley, C. P., Roberts, M. G., Lee, I. C. H., Grainger, D., Chaturvedi, A., Zhou, C., Fife, C. M., Morris, K. L., Gassio, A. F., et al. (2026) · medRxiv · doi:10.64898/2026.09.04.26362237
Self-citation
The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer
Li, X., Li, R., Wang, H., Zhang, P., Cao, D., & Zhang, F. (2026) · Immunologic Research · doi:10.1007/s12026-026-09844-5
Integrated single-cell and proteomic profiling of pancreatic neoplasia identifies tissue markers that outperform established diagnostic markers in distinguishing cancer from precursor lesionsPreprint
Tran, T. T., Nguyen, H. P. U., Fahrmann, J. F., Pham, D. T., Bui, L., Bui, N. H., & Schmidt, C. M. (2026) · medRxiv · doi:10.64898/2026.10.02.26364030
Prognostic and Spatial Organization of Tertiary Lymphoid Structures in Pancreatic Ductal Adenocarcinoma
Jia, Y., Zhang, M., Yang, H., Shi, Y., & Zhang, S. (2026) · Biomedicines · doi:10.3390/biomedicines14102287
Pharmacological reprogramming of myeloid suppression in solid tumors: mechanisms, evidence standards for immune conversion, and biomarker-informed combinations
Maletin, N., Denda, N., Kusturica, M. P., Rašković, A., Babović, S., & Golušin, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1986842
Spatial Proteomics Uncovers Immune Cell Neighborhoods and Tumor-Immune Interfaces in Pancreatic Ductal Adenocarcinoma
Yeung, J., Bai, Y., Qiu, H., Yeo, Y. Y., Chang, Y., Ng, M. S. F., Heij, L. R., Shah, E. A., Ma, Q., Reiss, D. J., et al. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101697
Targeting ferroptosis in major digestive system malignancies: regulatory networks and therapeutic opportunities
秦晓光, Wen, Q., Yang, Y., Sun, K., Guan, W., Ma, L., Sun, P., Zhang, M., Wu, Y., Li, L., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1945918

Authors: Liudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W., Lavoie, M. B., Robinson, P., Dias Costa, A., Väyrynen, S. A., Clancy, T. E., Rubinson, D. A., Link, J., Keith, D., Horton, W., Tempero, M. A., Vonderheide, R. H., Jaffee, E. M., Sheppard, B., Goecks, J., Sears, R. C., Park, B. S., Mori, M., Nowak, J. A., Wolpin, B. M., & Coussens, L. M.
Affiliations: Oregon Health & Science University (US)
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dana-Farber Cancer Institute (US)
Brigham and Women's Hospital (US)
University of California, San Francisco (US)
University of Pennsylvania (US)
Johns Hopkins University (US)
Corresponding author: Coussens, Lisa M.
ORCID: Liudahl, Shannon M.
Betts, Courtney B.
Sivagnanam, Shamilene
da Silva, Annacarolina
Yuan, Chen
Grossblatt-Wait, Alison
Väyrynen, Sara A.
Clancy, Thomas E.
Rubinson, Douglas A.
Link, Jason
Keith, Dove
Horton, Wesley
Tempero, Margaret A.
Vonderheide, Robert H.
Jaffee, Elizabeth M.
Sheppard, Brett
Goecks, Jeremy
Sears, Rosalie C.
Park, Byung S.
Mori, Motomi
Nowak, Jonathan A.
Wolpin, Brian M.
Coussens, Lisa M.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2021-03-16
Volume: 11
Issue: 8
Pages: 2014-2031
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-20-0841
PMC: PMC8338775
OpenAlex: W3136861954
Cited by: 164
References: 52
Citations by year: 2026: 31 · 2025: 26 · 2024: 34 · 2023: 40 · 2022: 20 · 2021: 13
FWCI: 9.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Stand Up To Cancer—Lustgarten Foundation Pancreatic Cancer Dream Team Translational Research Grant (SU2C-AACR-DT14-14)
National Institutes of Health (1U01 CA224012, U2C CA233280, R01 CA223150, R01 CA226909, R21 HD099367, UL1TR002369)
National Cancer Institute Human Tumor Atlas Network (U2C CA233280)
NIH (U01 CA210171, P50 CA127003, 1U01 CA224012, U2C CA233280, U54 CA209988, R01 CA196228, R01 CA186241)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
Keywords: pancreatic ductal adenocarcinoma, tumor immune microenvironment, leukocyte heterogeneity, myeloid cells, lymphoid cells, neoadjuvant therapy, predictive biomarkers, clinical outcomes, metastatic pancreatic cancer, tissue microarray, single-cell profiling
MeSH terms: Humans, Immunotherapy, Leukocytes, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks